NMR studies of V3 peptide complexes with antibodies suggest a mechanism for HIV-1 co-receptor selectivity

被引:0
作者
Sharon, M [1 ]
Rosen, O [1 ]
Anglister, J [1 ]
机构
[1] Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel
关键词
HIV-1; co-receptor; gp120; NMR of antibodies; V3;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The third variable region (V3) of the HIV-1 envelope glycoprotein gp120 is involved in gp120 binding to the chemokine receptors CCR5 and CXCR4, which serve as co-receptors in HIV-1 infection. The sequence of V3 determines whether the virus binds to CCR5 and infects predominantly macrophages (R5 virus) or to CXCR4 and infects mostly T-cells (X4 virus). This review summarizes structural information for V3 peptides in complex with HIV-1 neutralizing antibodies. Nuclear magnetic resonance studies of the V3 peptides led to the proposal of a mechanism for co-receptor selectivity. Experiments to further explore this mechanism and potential applications of V3 structural information are discussed.
引用
收藏
页码:601 / 612
页数:12
相关论文
共 50 条
[21]   HIV-1 GP120 V3 conformational and informational entropies [J].
Joel K. Weltman ;
Gail Skowron ;
George B. Loriot .
Journal of Molecular Modeling, 2006, 12 :362-365
[22]   HIV-1 GP120 V3 conformational and informational entropies [J].
Weltman, JK ;
Skowron, G ;
Loriot, GB .
JOURNAL OF MOLECULAR MODELING, 2006, 12 (03) :362-365
[23]   T=4 Icosahedral HIV-1 Capsid As an Immunogenic Vector for HIV-1 V3 Loop Epitope Display [J].
Zhang, Zhiqing ;
He, Maozhou ;
Bai, Shimeng ;
Zhang, Feng ;
Jiang, Jie ;
Zheng, Qingbing ;
Gao, Shuangquan ;
Yan, Xiaodong ;
Li, Shaowei ;
Gu, Ying ;
Xia, Ningshao .
VIRUSES-BASEL, 2018, 10 (12)
[24]   Serotyping HIV-1 with V3 peptides: detection of high avidity antibodies presenting clade-specific reactivity [J].
Casseb, J ;
Katzenstein, D ;
Winters, M ;
Brigido, LFM ;
Duarte, AJS ;
Hendry, RM .
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2002, 35 (03) :369-375
[25]   Conformational features of a synthetic cyclic peptide corresponding to the complete V3 loop of the ELI HIV-1 strain in water [J].
Vranken, WF ;
Budesinsky, M ;
Fant, F ;
Boulez, K ;
GrasMasse, H ;
Borremans, FAM .
COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, 1996, 61 (05) :742-750
[26]   HIV-1 gp120 V3 loop for structure-based drug design [J].
Sirois, S ;
Sing, T ;
Chou, KC .
CURRENT PROTEIN & PEPTIDE SCIENCE, 2005, 6 (05) :413-422
[27]   Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection [J].
Caldwell, David J. ;
Evans, Jeffery D. .
EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (18) :3231-3242
[28]   Seroreactivity to HIV-1 V3 subtypes A to H peptides of Argentinian HIV-positive sera [J].
Devito, C ;
Levi, M ;
Hinkula, J ;
Medina, RDF ;
Libonatti, O ;
Wigzell, H .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 17 (02) :156-159
[29]   An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120 [J].
Moseri, Adi ;
Tantry, Subramanyam ;
Sagi, Yael ;
Arshava, Boris ;
Naider, Fred ;
Anglister, Jacob .
VIROLOGY, 2010, 401 (02) :293-304
[30]   Conformational properties of HIV-1 gp120/V3 immunogenic domains [J].
Galanakis, PA ;
Spyroulias, GA ;
Rizos, A ;
Samolis, P ;
Krambovitis, E .
CURRENT MEDICINAL CHEMISTRY, 2005, 12 (13) :1551-1568